Search Results for: PULMONARY DELIVERY Pulmonary Delivery of
Articles
DRY POWDER FORMULATION - Preparing to Deliver the Next Generation of Inhaled Therapeutics April 29, 2024
Richard Johnson, PhD, outlines the trends and challenges within the inhaled drug delivery market. Specifically, DPI delivery will be explored, including how the challenges with dry powder formulation can be overcome and what the future holds for DPIs.
TFF Pharmaceuticals Announces Update on Clinical Programs March 20, 2024
TFF Pharmaceuticals, Inc. recently announced data updates and strategic prioritization of its clinical programs. Based on positive data from the...FORMULATION FORUM – Nanosuspensions - An Enabling Formulation for Improving Solubility & Bioavailability of Drugs December 4, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the role of excipients and methods for preparation and application of nanosuspensions in injectable, ocular, topical, and oral drug delivery.
PLATFORM TECHNOLOGY - The PTXΔLNP® Platform: On the Promise of Developing New LNPs for Tomorrow’s mRNA Therapies October 2, 2023
Charlotte Dunne, PhD, Katrin Radloff, PhD, and Leonidas Gkionis, PhD, review the PTXΔLNP platform and how it offers a synergistic sister technology to the mRNA platform to obtain potent mRNA-LNPs for therapeutic applications.
BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Trioxide Treatment Supporting Clinical Trial for Systemic Sclerosis September 19, 2023
BioSenic recently announced publication of data providing additional key indications of its lead API (Active Pharmaceutical Ingredient) arsenic trioxide (ATO)...Recipharm & Honeywell to Speed Development of Inhalers With Near-Zero Global Warming Potential Propellant August 17, 2023
Partnership will reduce environmental footprint of pressurized metered dose inhalers and accelerate transition to lower greenhouse gas respiratory care….
2023 Respiratory Drug Development eBook – Inhalers Trend Toward Sustainability & Targeted Control July 13, 2023
In this fourth annual Respiratory e-book, learn more about Porex and Nemera and their contributions to inhalation drug delivery and device design.
Thaerapy BV & Resyca BV Announce Exclusive License Agreement for Soft Mist Inhaler Technology June 15, 2023
Thaerapy BV and Resyca BV a joint venture of Medspray Pharma BV and Recipharm AB, a leader in the development of soft mist inhalers, recently announced today the signing of an exclusive license agreement for Resyca’s soft mist….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Putting Customers First June 5, 2023
Contributor Cindy H. Dubin speaks with several leading CDMOs from around the globe on their unique development and manufacturing capabilities and technologies, and presents real-world examples of how they have put these to use to produce innovative compounds, lower development costs, and shorten time to market.
DEVICE DEVELOPMENT - How to Ensure pMDI Drug Products Are Fit for the Future Market Landscape June 5, 2023
Ross Errington explores the latest developments in the pMDI segment and explains the steps pharmaceutical companies need to take to ensure their pMDI drug products are ready to thrive in a very different market environment.
Upperton Pharma Solutions Increases Oral Dosage Form Capabilities at Its Nottingham HQ May 31, 2023
Upperton Pharma Solutions has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK. Part of...Gerresheimer Announces Successful FDA Inspection at Peachtree City Site March 16, 2023
The Gerresheimer subsidiary in Peachtree City, GA, was named an approved Contract Manufacturer for VERO Biotech’s GENOSYL Delivery System (DS),...Paratek Pharmaceuticals Receives $36.4-Million Milestone Payment Associated With the Second Procurement of NUZYRA Under BARDA Project BioShield Contract January 5, 2023
Paratek Pharmaceuticals, Inc. recently announced the receipt of a $36.4-million milestone payment associated with the second procurement of NUZYRA (omadacycline)...NovaQuest Private Equity Announces Investment In Bend Bioscience to Broaden CoreRx Offering November 3, 2022
Bend Bioscience and QHP Capital (the management company for NovaQuest Private Equity) have recently announced plans to invest in a...FORMULATION FORUM - Lipid Nanoparticles: Tackling Solubility Challenges With Lipid-Based Technologies for Oral & Injectable Formulations October 10, 2022
Jim Huang, PhD, and Shaukat Ali, PhD, believe as more hydrophobic or brick dust and/or lipophilic or waxy molecules come out of discovery, amorphous solid dispersions (ASDs) and lipid based self-emulsifying microemulsions, nanoemulsions, liposomes, and nanoparticles are ideal for oral and injectable formulations.
NANOPARTICLE ENGINEERING - Lighting the Way to a Patient-Centric Future October 3, 2022
Christopher Worrall, PhD, discusses how nanoparticle engineering technologies could help improve compliance and patient outcomes, for both small-molecule and biological drugs, and how nanotechnology can help facilitate a shift toward more patient-centric medicine.
Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma & Fluidda September 22, 2022
Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products, recently announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging…..
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine September 6, 2022
MannKind Corporation recently announced it has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101) and is...2022 Respiratory Drug Development eBook - Demand Accelerates Devices July 8, 2022
This fourth annual Drug Development & Delivery Respiratory eBook highlights the pMDI development path, as well as the importance of a holistic approach to that development that includes the patient and all stakeholders across the product’s life cycle.
MERXIN & Gerresheimer Worked Successfully Together to Realize the Shortest Possible Time to Market for the MERXIN MRX003 Capsule DPI June 14, 2022
Gerresheimer has assumed responsibility for the industrialization of a dry powder inhaler for the treatment of respiratory ailments for MERXIN...
